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Abstract
Objective. Animal studies have demonstrated the extensive
interplay between the gut microbiota and immunity. Moreover, in
critically ill patients, who almost invariably suffer from a
pronounced immune response, a shift in gut microbiota composition
is associated with infectious complications and mortality. We
examined the relationship between interindividual differences in
gut microbiota composition and variation in the in vivo cytokine
response induced by bacterial lipopolysaccharide (LPS). Furthermore,
we evaluated whether an LPS challenge alters the composition of
the gut microbiota. Methods. Healthy male volunteers received an
intravenous bolus of 2 ng kg1 LPS (n = 70) or placebo (n = 8). Serial
plasma concentrations of tumor necrosis factor-a, interleukin (IL)-6,
IL-8 and IL-10 were measured, and subjects were divided into high
and low cytokine responders. Gut microbiota composition was
determined using 16s RNA gene sequencing of faecal samples
obtained 1 day before (baseline) and 1 day and 7 days following the
LPS challenge. Results. Baseline microbiota composition, analysed by
principal coordinate analysis and random forest analysis, did not
differ between high and low responders for any of the four
measured cytokines. Furthermore, baseline microbiota diversity
(Shannon and Chao indices) was similar in high and low responders.
No changes in microbiota composition or diversity were observed at
1 and 7 days following the LPS challenge. Conclusion. Our results
indicate that existing variation in gut microbiota composition does
not explain the observed variability in the LPS-induced innate
immune response. These findings strongly argue against the
interplay between the gut microbiota composition and the innate
immune response in humans.
Keywords: 16s RNA, gut microbiota, human endotoxaemia, innate
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INTRODUCTION
Over the last decades, it has become evident that
commensal microorganisms in the gut may
influence host physiology and pathology. Much
work in this field has been dedicated to the role
of the gut microbiota in host defence. For
instance, bone marrow-derived neutrophils
obtained from mice treated with broad-spectrum
antibiotics to deplete the gut microbiota exhibited
reduced killing of Streptococcus pneumonia and
Staphylococcus aureus ex vivo.1 In accordance, the
depletion of the gut microbiota in mice resulted
in reduced pulmonary cytokine levels and
increased bacterial dissemination following
infection with S. pneumonia, demonstrating the
protective role of a healthy gut microbiota
composition in pneumococcal pneumonia.2
Human data are sparse, although there are some
indications that variations in the gut microbiota
correlate with cytokine production by leucocytes
ex vivo stimulated with specific microbial stimuli.3
Furthermore, a decrease in total obligate
anaerobes in the gut was shown to be associated
with infectious complications and mortality in
critically ill patients.4 However, these results are
likely biased by several other factors, such as more
antibiotic administration in the sickest patients.
Evidence for a limited role of the microbiota in
regulation of the host response is emerging as
well. For instance, acute changes in bacterial
composition caused by a 7-day course of broad-
spectrum antibiotics in healthy volunteers exerted
only limited effects on cytokine release by
mononuclear cells upon ex vivo stimulation with
bacterial lipopolysaccharide (LPS)5, and a similar
course of antibiotics did not affect the in vivo
systemic cytokine response during experimental
endotoxaemia, a standardised, controlled and
reproducible model of systemic inflammation
consisting of intravenous LPS administration in
healthy volunteers.6 However, the question
remains whether naturally occurring
interindividual differences in microbiota
composition are associated with variation in the
in vivo immune response.
In addition to the above-mentioned putative
influence of the gut microbiota composition on
the systemic immune response, there are several
indications that the immune response may alter
the gut microbiota composition. For instance,
critical illness, which almost invariably involves
a pronounced immune response, is associated
with alterations in gut microbiota composition7,8,
which is in turn associated with increased
susceptibility to develop hospital-acquired
infections, sepsis and organ failure.9,10 Again,
many of these patients received antibiotics, and it
remains unknown whether an acute systemic
immune response by itself influences the gut
microbiota composition.
In this study, we investigated whether naturally
occurring interindividual differences in intestinal
microbiota composition are associated with
variation in the cytokine response during
experimental human endotoxaemia. Second, we
explored whether experimental endotoxaemia
causes alterations in the intestinal microbiota
composition up to 7 days following the LPS
challenge.
RESULTS
Subjects, symptoms and plasma cytokine
levels
There were no differences in baseline
demographic characteristics between the
experimental endotoxaemia and placebo groups
(Table 1). All subjects in the experimental
endotoxaemia group experienced flu-like
symptoms, reflected by an increase in total
symptom score from 0 [0–1] just before LPS
administration to a peak of 5 [3–6] at 1.5 h post-
LPS. Furthermore, both high and low responders
developed a transient systemic immune response,
reflected by an increase in plasma levels of pro-
inflammatory [tumor necrosis factor (TNF)-a,
interleukin (IL)-6 and IL-8] and anti-inflammatory
(IL-10) cytokines following the LPS administration,
which reverted to normal levels in the ensuing
hours (Figure 1 and Supplementary figure 1).
Subjects in the placebo group did not experience
any symptoms (median total symptom score of 0
at all time points) and did not display an increase
in plasma cytokine levels (Figure 1 and
Supplementary figure 1).
Associations between the baseline gut
microbiota composition and the LPS-
induced cytokine response
Baseline composition of the microbiota, analysed
using the Bray–Curtis dissimilarity index and
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plotted using principal coordinate analysis, did
not differ between high and low responders for
any of the four measured cytokines (Figure 2).
Performing the same analysis, but using quartiles
instead of median area under the
concentration–time curve (AUC) cytokine levels,
also revealed no relationship between baseline
composition of the gut microbiota and the
cytokine response (Supplementary figure 2). For
microbiota diversity, no differences were found
either between high and low cytokine
responders (Figure 3 and Supplementary
figure 3). Finally, random forest analysis showed
no difference between high and low cytokine
responders in abundance of taxa present in the
gut (Table 2).
Table 1. Baseline demographic and clinical data
Parameter All subjects (n = 78) LPS (n = 70) Placebo (n = 8) P-value
Age (years) 22 [20–24] 22 [20–24] 21 [19–23] 0.22
Temperature (°C) 36.6 [36.4–37] 36.6 [36.4–37] 36.6 [36.2–37] 0.74
Weight (kg) 76.8 [70–83] 76.9 [70.3–82.3] 75.7 [69.0–89.8] 0.90
MAP (mmHg) 98 [93–109] 98 [93–103] 98 [94–99] 0.31
Data are presented as median [IQR]; P-values are calculated using Mann–Whitney U-tests (LPS vs placebo group).
MAP, mean arterial blood pressure.
Figure 1. Plasma cytokine levels of subjects intravenously challenged with lipopolysaccharide (LPS) or receiving placebo. (a) Tumor necrosis factor
(TNF)-a. (b) Interleukin (IL)-6. (c) IL-8. (d) IL-10. Subjects who were challenged with LPS were divided into two groups based on their area under
the concentration–time curve plasma cytokine levels (AUC, reflecting total cytokine production over time). Low responders have AUC plasma
cytokine levels below the median, and high responders have AUC plasma cytokine levels above the median. Only subjects who, apart from LPS,
received a placebo or an intervention that did not significantly affect the cytokine response were included, on a per-cytokine base. Data are
presented as mean  SEM. P-values were calculated by two-way repeated-measures ANOVA (time*group interaction term).
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The influence of the LPS-induced systemic
immune response on the intestinal
microbiota composition
Experimental human endotoxaemia induced a
profound systemic inflammatory response,
reflected by the aforementioned increase in
circulating cytokines and the development of flu-
like symptoms and fever, but no changes in
microbiota composition or diversity were observed
1 and 7 days following endotoxaemia (phylum
level shown in Figure 4 and genus level in
Supplementary figure 4).
DISCUSSION
In the present study, we demonstrate that existing
interindividual differences in gut microbiota
composition are not associated with variation in
in vivo cytokine responses during experimental
human endotoxaemia. Second, we demonstrate
that the LPS-induced systemic immune response
does not alter the composition of the gut
microbiota in the following week. These results
strongly argue against a relevant interplay
between the gut microbiota composition and the
innate immune response in humans.
Figure 2. Principal coordinate analysis (PCoA) of baseline gut microbiota composition in high (blue dots) and low (red dots) cytokine responders
upon lipopolysaccharide (LPS) challenge. (a) Tumor necrosis factor (TNF)-a (high responder n = 32, low responder n = 32). (b) Interleukin (IL)-6
(high responder n = 27, low responder n = 27). (c) IL-8 (high responder n = 32, low responder n = 32). (d) IL-10 (high responder n = 23, low
responder n = 24). Subjects were divided into two groups based on their area under the concentration–time curve plasma cytokine levels (AUC,
reflecting total cytokine production over time). Low responders have AUC plasma cytokine levels below the median, and high responders have
AUC plasma cytokine levels above the median. Only subjects who, apart from LPS, received a placebo or an intervention that did not significantly
affect the cytokine response were included, on a per-cytokine base. The horizontal axis reflects principal coordinate 1, and the vertical axis
reflects principal coordinate 2 with their corresponding percentages of explained variance. PERMANOVA on the Bray–Curtis dissimilarity index:
TNF-a: F-value = 1.14, R2 = 0.02, P = 0.21. IL-6: F-value = 1.01, R2 = 0.02, P = 0.46. IL-8: F-value = 1.29, R2 = 0.02, P = 0.08. IL-10: F-
value = 1.17, R2 = 0.023, P = 0.19.
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Results obtained in various animal models
demonstrated that microbiota dysbiosis is
associated with increased susceptibility to
infections.11,12 However, whereas broad-spectrum
antibiotic-induced depletion of the microbiota in
healthy volunteers drastically lowered diversity
and decreased absolute numbers of bacteria, no
effects on the cytokine response were observed
during experimental human endotoxaemia.6 This
suggests that acute changes in microbiota
composition do not influence the innate immune
response in humans. In contrast, chronically
existing differences in microbiota composition
between individuals may impact susceptibility to
Figure 3. Alpha diversity in gut microbiota at baseline, reflected by the Shannon diversity index and the Chao1 index, in high (blue dots) and
low (red dots) cytokine responders upon lipopolysaccharide (LPS) challenge. (a) Tumor necrosis factor (TNF)-a (high responder n = 32, low
responder n = 32). (b) Interleukin (IL)-6 (high responder n = 27, low responder n = 27). (c) IL-8 (high responder n = 32, low responder n = 32).
(d) IL-10 (high responder n = 23, low responder n = 24). Subjects were divided into two groups based on their area under the concentration–
time curve plasma cytokine levels (AUC, reflecting total cytokine production over time). Low responders have AUC plasma cytokine levels below
the median, and high responders have AUC plasma cytokine levels above the median. Only subjects who, apart from LPS, received a placebo or
an intervention that did not significantly affect the cytokine response were included, on a per-cytokine base. Data are presented as box-and-
whisker plots, with whiskers representing the lowest and highest values within 1.5*interquartile range (IQR). P-values were calculated by Mann–
Whitney U-tests.
Table 2. Area under the receiver operating characteristic curve
values using microbiota composition at baseline as the independent
variable and high vs low responders (based on AUC cytokine levels)
as the dependent variable
Groups
Area under the curve
OTU Genus
IL-6 high vs low responder 0.596 0.476
IL-8 high vs low responder 0.551 0.609
IL-10 high vs low responder 0.525 0.548
TNF-a high vs low responder 0.495 0.565
There were no differences in taxa at baseline, which explain the
extent of the cytokine response.
OTU, operational taxonomic unit.
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auto-immune diseases13,14, as well as the risk to
develop other diseases.15–19 For example, it is
argued that the more pro-inflammatory
phenotype observed in elderly or obese
individuals can be explained by differences in
their microbiota composition compared with
young and lean individuals.15,20,21 Although these
observations might suggest that these chronically
existing interindividual differences in microbiota
composition influence human immunity, these
associations are likely to be confounded by
various other factors. Furthermore, the effect size
is likely small, as variation in microbiota
composition was found to explain only 10% of
the variation in ex vivo cytokine production by
leucocytes of healthy volunteers.3 In our study,
all subjects developed a transient systemic
immune response. However, this immune
response evoked by LPS, a microbiota-derived
compound, is not influenced by an individual’s
gut microbiota composition. So, in addition to
the previously reported absence of effects of
acute depletion of the microbiota by broad-
spectrum antibiotics on the LPS-induced innate
immune response6, our findings indicate the
absence of an association between chronically
existing interindividual differences in microbiota
and the immune response. To our knowledge,
the present study is the first to investigate the
proposed interplay between the variability of
existing intestinal microbiota and the systemic
innate immune system in humans under
controlled circumstances. These findings are not
in line with previous animal studies or
observational patient studies, and illustrate the
importance of translating findings obtained in
animals to humans and from uncontrolled to
controlled settings.
Figure 4. Effect of lipopolysaccharide (LPS) challenge on gut microbiota composition. (a) Principal coordinate analysis (PCoA) of microbiota
composition over time following the LPS challenge (n = 63, paired samples across time points). PERMANOVA on the Bray–Curtis dissimilarity
index: F-value = 0.44, R2 = 0.01, P = 1.00. (b) Gut microbiota diversity over time following the LPS challenge (n = 63, paired samples across time
points), reflected by the Shannon index and the Chao1 index. P-values were calculated by Friedman tests. (c) Relative abundance of gut
microbiota (phylum level) over time following the LPS challenge (n = 63, paired samples across time points).
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In addition, we demonstrate that, despite
induction of a pronounced systemic immune
response by LPS administration, the gut
microbiota composition remains unaltered for up
to a week. These findings in healthy volunteers
contradict results obtained in septic and non-
septic critically ill patients admitted to the ICU,
where a shift in microbiota composition was
observed in the days after ICU admission.7,8,22 This
may be because of the fact that experimental
human endotoxaemia mimics a short-lived
systemic inflammatory response and cannot
recapitulate the entire disease spectrum observed
in patients admitted to the ICU with sepsis or
other conditions. Furthermore, the findings in ICU
patients were obtained in an uncontrolled setting,
where not only systemic inflammation but also
the use of antibiotics, severity of organ
dysfunction and many other confounding factors
are likely to play a role. Irrespective of the cause
of microbiota disruption in critically ill patients,
restoration of a healthy microbiota may
nevertheless still be important for improving
outcomes of these patients.
Our study has several limitations. First, our study
population consisted of healthy Caucasian young
men, with little variation in age and weight and a
relatively limited diversity in gut microbiota at
baseline. For example, in patients with or without
Alzheimer’s disease, the difference in the Chao1
index was more than 5018, compared to
differences of less than 25 in our study
population. Therefore, the interindividual
differences in microbiota composition in our
relatively homogenous group of young volunteers
may have been too small to cause differences in
the immune response. As such, the possibility
remains that more pronounced differences in
diversity indices, for instance related to health
parameters15, may be associated with differences
in immunity. Second, as briefly touched on
before, experimental human endotoxaemia does
not fully recapitulate the entire disease spectrum
observed in ICU patients with sepsis or other
conditions, and is also not fully comparable with
the often severe animal models used in the sepsis
research field. However, our human model
captures many hallmarks of the early septic
immune response. These similarities are not
confined to the inflammatory response alone, but
also comprise clinical parameters and organ-
specific changes, such as cardiovascular (reduced
left ventricular contractility, hyperdynamic
circulation), haematological (reduced platelet
count and function) and endocrinological
(catecholamine and cortisol stress response)
alterations. Especially of relevance to the current
study, experimental human endotoxaemia results
in increased gut permeability23, which is also
observed in sepsis patients. Strengths of our study
include the large sample size for an endotoxaemia
study and the highly standardised, controlled and
reproducible set-up. As such, the absence of
confounding factors enables meticulous dissection
of the interplay between the intestinal microbiota
composition and the innate immune response.
In conclusion, we demonstrate that no
relationship exists between existing gut
microbiota composition and the cytokine response
induced by an LPS challenge in healthy
volunteers. Furthermore, the LPS-induced systemic
innate immune response does not alter the gut
microbiota composition in the following week.
Our data suggest that it is unlikely that
interindividual differences in microbiota
composition determine the extent of the immune
response and that the systemic immune response
per se does not account for the change in
microbiota composition observed in critically ill
patients. These observations strongly argue
against the relevant interplay between the gut
microbiota composition and the innate immune
response in humans, indicating that the
therapeutic value of modulation of the gut




During the conduct of four experimental human
endotoxaemia studies, data were obtained from a total of 78
healthy male volunteers.24–28 All studies were approved by
the local ethics committee (CMO Arnhem-Nijmegen,
registration numbers 2013-041, 2013-290, 2015-2058 and
2015-2079) and registered at ClinicalTrials.gov: NCT01944228,
NCT01978158, NCT02642237 and NCT02675868. Written
informed consent was obtained from all study participants,
and all procedures were in accordance with the Declaration
of Helsinki, including latest revisions. Seventy subjects
received LPS (further detailed below), whereas 8 subjects
received placebo (saline). For the analyses aimed at
determining the relationship between variation in the
baseline microbiota composition and the cytokine response,
we only included subjects who, apart from LPS, received a
placebo or an intervention that did not significantly affect
the cytokine response. The latter was determined on a per-
cytokine basis.
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For the analyses aimed at determining the effects of the
LPS-induced systemic immune response on microbiota
composition, we included all subjects who received LPS.
Seven subjects were excluded because of insufficient
amounts of faecal material to extract bacterial DNA from,
resulting in a total of 63 remaining subjects for these
analyses.
Subjects were healthy, non-smoking, male volunteers,
18–35 years old, without febrile illness or use of any
medication (including antibiotics) during the month before
the experiment. They had a normal physical examination,
routine blood investigation and electrocardiography upon
screening before the start of the experiments. Caffeine and
alcohol intake was not allowed within 24 h before the start
of the experiments and subjects refrained from food 12 h
before the start of the experiment.
Experimental human endotoxaemia
procedures
Endotoxaemia experiments were conducted at the research
unit of the intensive care department of the Radboud
University Medical Center according to our standardised
protocol.23 In all subjects, an arterial line was placed in the
radial artery for blood sampling and continuous monitoring
of blood pressure, and a venous cannula was placed for
hydration and LPS administration. Heart rate was
monitored using a 3-lead electrocardiogram, and body
temperature was measured every 30 min. The severity of
flu-like symptoms (headache, nausea, shivering, muscle and
back pain) was scored every 30 min on a scale ranging from
0 to 5 per symptom, resulting in a total score of 0–25
points.
Subjects received an intravenous bolus of 2 ng kg1
purified LPS (US Standard Reference Endotoxin Escherichia
coli O:113, obtained from the Pharmaceutical Development
Section of the National Institutes of Health, Bethesda, MD,
USA) or matched bolus volume of NaCl 0.9% (placebo
group) at T = 0. All subjects received 1.5 L of 2.5% glucose/
0.45% saline solution during 1 h before LPS/placebo
administration, followed by 150 mL h1 until 6 h after
LPS/placebo administration and 75 mL h1 until the end of
the experiment.
Cytokine and leucocyte analysis
Before (T = 0) and at 60, 90, 120, 180, 240, 360 and
480 min after LPS administration, blood samples were
obtained from the arterial line and collected in
ethylenediaminetetraacetic acid (EDTA)-containing
vacutainers. Blood was immediately centrifuged at 2000 g
for 10 min at 4°C, and plasma was stored at 80°C until
analysis. Concentrations of TNF-a, IL-6, IL-8 and IL-10 in all
samples used for the analyses described in the current
study were measured in one batch using a Luminex assay
(R&D Systems; Abingdon Science Park, UK). The lower
detection limit was 2 pg mL1 for all cytokines. Leucocyte
counts were determined in EDTA-anticoagulated blood by
the Department of Laboratory Medicine of the Radboud
University Medical Center (Sysmex XE-5000; Sysmex
Nederland B.V., Etten-Leur, the Netherlands).
Microbiota analysis
Subjects collected faecal samples at home 1 day before and
1 day and 7 days after the endotoxaemia experiment. These
samples were stored at 20°C and transported to the study
centre for storage at 80°C. Bacterial DNA was extracted
using a bead-beating protocol, and the extracted DNA was
used for 16s rRNA gene sequencing (Illumina MiSeq
sequencing) as described previously.29 Data were processed
using the NG-Tax software package.30
Statistical analysis
The distribution of data was tested using the Shapiro–Wilk
tests. Parametric data are presented as mean  SEM,
whereas non-parametric data are presented as median
[interquartile range]. The differences between groups were
analysed using two-way repeated-measures analysis of
variance (two-way ANOVA, time*group interaction term).
To increase sensitivity to detect possible differences in
microbiota composition at baseline between high and low
cytokine responders, several analyses were performed:
subjects were divided into two (above and below median)
or four (quartiles) groups based on their AUC (reflecting
total cytokine production over time) plasma cytokine levels.
To analyse microbial beta diversity, which describes the
diversity in a microbial community between different
samples, principal coordinate analysis (PCoA) of the
different groups was performed in an unconstrained way
and permutational multivariate analysis of variance
(PERMANOVA) on the Bray–Curtis dissimilarity index was
performed in MicrobiomeAnalyst.31,32 Furthermore, random
forest analyses using microbiota composition at baseline as
the independent variable and AUC cytokine levels as
dependent variables were performed to identify taxa that
may be differently abundant in the gut of high cytokine
responders compared with low cytokine responders. The
Shannon diversity index and the Chao1 index were used as
measures of alpha diversity of the gut microbiota.33,34 The
Chao1 estimates the numbers of unique operational
taxonomic unit (OTUs) in a sample (microbial richness). The
Shannon index takes into account richness and evenness. To
analyse the differences in alpha diversity between high and
low responders, the Mann–Whitney U-tests were used. For
our second objective – determining whether an LPS
challenge alters the gut microbiota composition – the
above-described principal coordinate analysis was used to
compare gut microbiota composition at baseline vs days 1
and 7. Additionally, the differences in alpha diversity at
baseline vs days 1 and 7 were assessed using Friedman tests.
Statistical analyses were performed using GraphPad Prism
5.03 (GraphPad Software Inc, San Diego, California, USA),
SPSS for Windows 22.0 (SPSS Inc, Chicago, IL, USA), R
(package ‘randomForest’, version 4.6-14) and
MicrobiomeAnalyst.31,32
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